Adenosine A2A receptors in Parkinson’s disease treatment (original) (raw)

Dopamine agonists and Parkinson's disease

jeff beckman

Clinical Neurology and Neurosurgery, 1984

View PDFchevron_right

Drug treatment of Parkinson’s disease

benjamin drukarch

Biochemical Pharmacology, 2000

View PDFchevron_right

Adenosine A1 Receptors in the Central Nervous System: Their Functions in Health and Disease, and Possible Elucidation by PET Imaging

Aren van Waarde

Current Medicinal Chemistry, 2011

View PDFchevron_right

Adenosine: a prototherapeutic concept in neurodegeneration

Dag von Lubitz

1995

View PDFchevron_right

Therapeutic Potentials of Adenosine Receptors: The State of The Art

Pran kishore deb

Current Pharmaceutical Design, 2019

View PDFchevron_right

Emerging Therapies in the Pharmacological Treatment of Parkinson???s Disease

Amos Korczyn

Drugs, 2002

View PDFchevron_right

Potential of Adenosine-System-Based Therapies in the Treatment of Neuroimmune Disorders

Ivo Peixoto

2012

View PDFchevron_right

Ligand-Dependent Activation and Deactivation of the Human Adenosine A2A Receptor

John Shelley

Journal of the American Chemical Society, 2013

View PDFchevron_right

Parkinson’s disease updates: Addressing the pathophysiology, risk factors, genetics, diagnosis, along with the medical and surgical treatment

Kirtish Acharya

Annals of Medicine and Surgery, 2023

View PDFchevron_right

Targeting adenosine A 2A receptors in Parkinson's disease

Kjell Fuxe

Trends in Neurosciences, 2006

View PDFchevron_right

Ligand-Dependent Activation and Deactivation of the Human Adenosine A2A Receptor

John Shelley

Journal of the American Chemical Society, 2013

View PDFchevron_right

An Update on Adenosine A2A Receptors as Drug Target in Parkinson's Disease

luisa Arna

CNS & Neurological Disorders - Drug Targets, 2011

View PDFchevron_right

Adenosine Receptor Alterations in Nervous Pointer Dogs

Ehud Klein

Clinical Neuropharmacology, 1987

View PDFchevron_right

Increased adenosine deaminase serum activity

antonio josé franco useche

Revista Latinoamericana …, 2010

View PDFchevron_right

A 2A adenosine receptor ligand binding and signalling is allosterically modulated by adenosine deaminase

Carme Lluís, Josefa Mallol, Enric I. Canela

Biochemical Journal, 2011

View PDFchevron_right

Consequences of eliminating adenosine A1 receptors in mice

Lydia Giménez-llort

2003

View PDFchevron_right

Adenosine A2Areceptor antagonist treatment of Parkinson’s disease

Francesco Bibbiani

Neurology, 2003

View PDFchevron_right

New therapies for the treatment of Parkinson's disease: Adenosine A2A receptor antagonists

Jadwiga Wardas

Life Sciences, 2005

View PDFchevron_right

Supplement 4: Canadian Guidelines on Parkinson's Disease

Hrishikesh Kumar

The Canadian Journal of Neurological Sciences, 2012

View PDFchevron_right

Parkinson Disease

Arthur Friedlander

The Journal of the American Dental Association, 2009

View PDFchevron_right

Adenosine A2A-Receptor Antagonism and Pathophysiology of Parkinson’s Disease and Drug-Induced Movement Disorders

Jaime Kulisevsky

European Neurology, 2012

View PDFchevron_right

Hyperresponsiveness to adenosine in sensitized Wistar rats over-expressing A1 receptor

Silvana Morello

European Journal of Pharmacology, 2012

View PDFchevron_right

Pharmacological evidence for different populations of postsynaptic adenosine A2A receptors in the rat striatum

César Quiroz

Neuropharmacology, 2011

View PDFchevron_right

Experimental models of Parkinson's disease

Léon Tremblay

Nature Reviews Neuroscience, 2001

View PDFchevron_right

Treatment of Parkinson's disease with NADH

Björn Lindvall

Acta Neurologica Scandinavica, 2009

View PDFchevron_right

Cortical inhibition in Parkinson's disease

Maurizio Inghilleri

Brain, 1996

View PDFchevron_right

Modulation of apoptosis by adenosine in the central nervous system: a possible role for the A3 receptor

Dag von Lubitz

Annals of the New …, 1997

View PDFchevron_right

A2A adenosine receptor overexpression and functionality, as well as TNF- levels, correlate with motor symptoms in Parkinson's disease

Pier Borea

The FASEB Journal, 2010

View PDFchevron_right

Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease

Christa Mueller

Pharmacology & Therapeutics, 2011

View PDFchevron_right

Cell Based Therapies in Parkinson’s Disease

Madhuri Behari

Annals Of Neurosciences, 2011

View PDFchevron_right

Parkinson's Disease: An update on Pathophysiology, Epidemiology, Diagnosis and Management Part 5: Management Strategies

Abdulrazak Abyad

Middle East Journal of Internal Medicine, 2020

View PDFchevron_right

Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease

Imtiaz Ahmed

Neurology, 2011

View PDFchevron_right

Pharmacological Therapy in Parkinson's Disease: Focus on Neuroprotection

László Vecsei

CNS Neuroscience & Therapeutics, 2010

View PDFchevron_right

Recent advances in cell-based therapy for Parkinson disease

Ole Isacson

Neurosurgical FOCUS, 2008

View PDFchevron_right

Caffeine and Progression of Parkinson Disease

Jay Schneider

Clinical Neuropharmacology, 2015

View PDFchevron_right